公开(公告)号：US20200277378A1

公开(公告)日：2020-09-03

申请号：US16764102

申请日：2018-11-16

Applicant: Novartis AG

Inventor： Catherine Anne Sabatos-Peyton ,  Jennifer Marie Mataraza ,  Kenzie MacIsaac ,  Eunice Kwak ,  Jason Faris ,  Glenn Dranoff ,  Marion Wiesmann ,  Fiona Sharp ,  Adam Crystal ,  John Scott Cameron ,  Robert Martin Strieter ,  Lilli Petruzzelli ,  Shamsah Kazani ,  David Andrew Sandham ,  Neil John Press ,  Keith Hoffmaster

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

Abstract: Combination therapies comprising PD-1 inhibitors and other therapeutic agents used to treat or prevent cancerous conditions and disorders as follow. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and a CSF-1/1R binding agent for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and an inhibitor of either TIM-3, C-MET or A2aR for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a LAG-3 inhibitor and (i) an inhibitor of either TGF-beta, TIM-3, C-MET, IL-1b or MEK or (ii) a GITR agonist or (iii) an A2aR antagonist or (iv) a CSF-1/1R binding agent for treating a breast cancer. Combination therapies of two agents which are a PD-1 inhibitor and a CXCR2 inhibitor for treating a pancreatic cancer, a colorectal cancer, a lung cancer or a breast cancer.

公开(公告)号：US20200237773A1

公开(公告)日：2020-07-30

申请号：US16634924

申请日：2018-08-01

Applicant: Novartis AG

Inventor： Susan Moody ,  Lilli Petruzzelli ,  Jeffrey Engelman

IPC: A61K31/55 ,  A61K31/5377 ,  A61P35/00

Abstract: This invention relates to a pharmaceutical combination comprising (a) a third generation EGFR tyrosine kinase inhibitor and (b) a Raf inhibitor, particularly for use in the treatment of a cancer, particularly a lung cancer. This invention also relates to uses of such a combination for the preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.